The drug by all appearances is working. No other drug works to a remotely comparable degree of efficacy (especially by the ADCS-ADL measure). Perhaps nothing is a lock until it happens, but unless the situation outlined in the first two sentences changes, there is zero chance that no big pharma company wants to share in the financial rewards of a new SOC in Alzheimer's.
Market Data 
Markets 
AI
